HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Paul Vogt Peter Roth Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Brueck, M. Articles by Heidt, M. C. Search for Related Content PubMed PubMed Citation Articles by Brueck, M. Articles by Heidt, M. C. Related Collections Valve disease

Eur J Cardiothorac Surg 2007;32:108-112. doi:10.1016/j.ejcts.2007.03.031
Copyright © 2007, European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved

Antiplatelet therapy early after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk factors

^a Department of Cardiology, Clinic of Wetzlar, Germany
^b Department of Cardiovascular Surgery, University of Giessen, Germany
^c Department of Cardiovascular Surgery, Kerckhoff-Clinic, Bad Nauheim, Germany

Received 27 December 2006; received in revised form 13 March 2007; accepted 20 March 2007.

^_* Corresponding author. Address: Clinic of Wetzlar, Department of Cardiology, Forsthausstrasse 1, D-35578 Wetzlar, Germany. Tel.: +49 6441 792327; fax: +49 6441 792328. (Email: Martin.Brueck{at}hkw.med.uni-giessen.de).

Background: The use of antithrombotic therapy during the postoperative period after biological aortic valve replacement (AVR) in patients without thromboembolic risk factors remains controversial. Treatment with warfarin is recommended for the first 3 months after biological AVR. The use of antiplatelet therapy – mainly aspirin (ASA) – is suggested as an alternative treatment but its efficacy is still unsettled. Due to the increased risk of bleeding complications even no use of any antithrombotic or antiplatelet therapy was advocated. Given this ongoing dispute, the aim of this retrospective double-institutional study was to evaluate the necessity of antiplatelet treatment by ASA with no postoperative antiplatelet therapy in terms of survival, major bleedings and cerebral thromboembolism of patients undergoing biological AVR without thromboembolic risk factors. Methods: From January 2001 to December 2003, 288 consecutive patients (72.8 ± 7.5 years, 134 males) with sinus rhythm and no other thromboembolic risk factors underwent single biological AVR with porcine or bovine pericardial valves without concurrent coronary artery bypass graft surgery. By surgeons preference, 100 mg ASA was given to 132 patients, and 156 patients received no antiplatelet therapy. Patients were followed for cerebral ischemic events, major bleedings, need for repeat operation, NYHA class and survival at three time intervals postoperatively (30 days, 3 and 12 months). Results: None of all patients died during the operation. Mortality within 30 days was 3.8% in the ASA and 3.9% in the no ASA group (p = 0.777). There were no statistically significant differences for cerebral ischemia within 3 months after AVR (ASA 0.8% vs no ASA 1.3%: p = 0.884) and 3 to 12 months after AVR (ASA 0.8% vs no ASA 0%; p = 0.933). Major bleedings occurred in two ASA-treated patients and in one patient without antiplatelet therapy (p = 0.884). The incidence of NYHA class III–IV after 3 months (1.5% vs 1.9%; p = 0.850) and 12 months (9.0% vs 5.1%; p = 0.278) were similar, as were the need for repeat operative AVR after 12 months (0.8% vs 0.6%; p = 0.553). Survival rates at 12-month follow-up were 95.5% for ASA treatment and 94.9% for no ASA treatment (p = 0.963). Conclusions: In patients without thromboembolic risk factors undergoing biological AVR administration of ASA confers no advantage compared to no antiplatelet therapy. Functional status, thromboembolic events and survival were not adversely affected by withholding any antiplatelet therapy. Guidelines need to be reviewed for the antithrombotic therapy of patients without risk factors undergoing bioprosthetic AVR.

Key Words: Anticoagulation • Valves • Prosthesis • Thromboembolism • Antiplatelets

This article has been cited by other articles:

				J. Dunning, M. Versteegh, A. Fabbri, A. Pavie, P. Kolh, U. Lockowandt, S. A.M. Nashef, and on behalf of the EACTS Audit and Guidelines Commit Guideline on antiplatelet and anticoagulation management in cardiac surgery. Eur. J. Cardiothorac. Surg., July 1, 2008; 34(1): 73 - 92. [Abstract] [Full Text] [PDF]

				J. I. Aramendi and C.-A. Mestres Antithrombotic therapy after bioprosthetic aortic valve replacement Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 529 - 530. [Full Text] [PDF]

				A. Colli, J.-P. Verhoye, R. Heijmen, J. T. Strauch, J. A.J. Hyde, D. Pagano, M. Antunes, H. Koertke, S. K. Ohri, D. H. L. Bail, et al. Antithrombotic therapy after bioprosthetic aortic valve replacement: ACTION Registry survey results Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 531 - 536. [Abstract] [Full Text] [PDF]

				J. Nowell and M. Jahangiri Antiplatelet therapy after bioprosthetic aortic valve replacement is unnecessary in patients without thromboembolic risk Eur. J. Cardiothorac. Surg., December 1, 2007; 32(6): 945 - 945. [Full Text] [PDF]